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Abstract: Eye drops of poorly soluble drugs are frequently formulated as suspensions. Bioavailability
of suspended drug depends on the retention and dissolution of drug particles in the tear fluid, but
these factors are still poorly understood. We investigated seven ocular indomethacin suspensions
(experimental suspensions with two particle sizes and three viscosities, one commercial suspension)
in physical and biological tests. The median particle size (d50) categories of the experimental
suspensions were 0.37–1.33 and 3.12–3.50 µm and their viscosity levels were 1.3, 7.0, and 15 mPa·s.
Smaller particle size facilitated ocular absorption of indomethacin to the aqueous humor of albino
rabbits. In aqueous humor the AUC values of indomethacin suspensions with different particle
sizes, but equal viscosity, differed over a 1.5 to 2.3-fold range. Higher viscosity increased ocular
absorption 3.4–4.3-fold for the suspensions with similar particle sizes. Overall, the bioavailability
range for the suspensions was about 8-fold. Instillation of larger particles resulted in higher tear fluid
AUC values of total indomethacin (suspended and dissolved) as compared to application of smaller
particles. Despite these tear fluid AUC values of total indomethacin, instillation of the larger particles
resulted in smaller AUC levels of indomethacin in the aqueous humor. This suggests that the small
particles yielded higher concentrations of dissolved indomethacin in the tear fluid, thereby leading
to improved ocular bioavailability. This new conclusion was supported by ocular pharmacokinetic
modeling. Both particle size and viscosity have a significant impact on drug concentrations in the
tear fluid and ocular drug bioavailability from topical suspensions. Viscosity and particle size are
the key players in the complex interplay of drug retention and dissolution in the tear fluid, thereby
defining ocular drug absorption and bioequivalence of ocular suspensions.
Keywords: ocular absorption; indomethacin; suspension; bioequivalence; dissolution; particle
size; viscosity
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1. Introduction
Topically applied eyedrops are the most commonly used dosage form in ocular drug
treatment. They are used in the treatment of anterior segment diseases, such as infections,
inflammatory conditions, and glaucoma. Nevertheless, ocular bioavailability of drugs after
eyedrop administration to rabbits is limited to less than 5% of the instilled dose, often less
than 1% [1]. This is due to several limiting factors: (1) the permeation barrier of the corneal
epithelium [2]; (2) rapid drainage of the instilled drug from the ocular surface [3]; and (3)
effective transconjunctival drug absorption into the systemic blood circulation [4,5]. In
humans, the blinking rate and solution drainage from the ocular surface is also fast and
the corneal barrier is tight, indicating low ocular bioavailability [6]. Topical ocular drug
delivery is illustrated in Figure 1.
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Drug concentrations in ophthalmic eyedrop solutions are usually in the range of 0.1%
to 4%, but such drug concentrations in solution are difficult to reach for hydrophobic
drugs, and therefore many topical eyedrop formulations are suspensions. Even though
ophthalmic suspensions are commonly used, their biopharmaceutical properties are poorly
understood. Very few systematic studies involving ocular sus ensions have been pub-
lished, and s veral studies date from the 1980s and 1990s [7–12]. These pivotal reports
demonstrate that particle size affects the ocular absorption of dexamethasone [7] and
fluorometholone [8] from topically instilled suspensions in rabbits. Increased drug absorp-
tion from nanosized particles has also been observed [13–18]. These studies suggest that
dissolution of suspended particles plays a role in ocular drug absorption.
Biopharmaceutical impact and interplay of formulation factors, such as viscosity and
particle size, have not been systematically investigated or modeled. In the eye, these factors
may have a significant impact on ocular drug absorption because the typical eye drop
volume (30–50 µL) is much larger than the normal volume of weakly buffered lacrimal fluid
(7 µL) [19]. Th refore, t is likely that the formulation features (pH, visco ity, excipients)
of the eyedrop determine the physical–chemical conditions on the ocular surface an ,
therefore, significantly influence drug absorption from the topical ophthalmic suspensions.
It is important to build a better understanding of drug delivery from ophthalmic
suspensions. Understanding the critical biopharmaceutical factors of ocular topical suspen-
sions would help in the design of optimized formulations for poorly soluble drugs. On the
other hand, understanding of the suspensions should foster the regulatory guidance for
bioequivalent generic ocular suspensions, thus avoiding expensive and time-consuming
harmacokinetic studies. Aqu ous humor sampling from patients undergoing cataract
urgery is recommended by the FDA t investigate bioequivalence of c rticosteroid sus-
pensions [20].
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We investigated seven indomethacin suspensions (one commercial and six experi-
mental formulations) using physical characterization methods and ocular drug absorption
studies in vivo in rabbits. Kinetic simulation models were utilized to aid in interpretation
of the data.
2. Materials and Methods
Materials: One commercial indomethacin suspension (Indom® 0.5%) and six test sus-
pensions (INDO1, INDO2, INDO3, INDO4, INDO5, INDO6) with 0.5% of indomethacin
were investigated. Indom® 0.5% suspension (Alfa Intes, Lot. 4115 Exp. 08.2017) was
purchased from Casoria, Italy. The excipients of Indom® 0.5% include hydroxypropyl
methylcellulose (HPMC) 4000, sodium dihydrogen phosphate dihydrate, disodium phos-
phate dodecahydrate, sodium chloride, edetate disodium, methylparaben, propylparaben,
and purified water. Excipient concentrations were analyzed with UPLC (see Supplemen-
tary Materials).
Pharmaceutical grade indomethacin from Orion Pharma (Espoo, Finland) was used to
prepare the six test suspensions (INDO1-INDO6). HPMC E5 was obtained from Dow Chem-
icals (Dow Chemicals, Midland, MI, USA), HPMC 4000 was obtained from Sigma-Aldrich
(Sigma-Aldrich, St. Louis, MO, USA), while the HPMC K35M (Benecel™) was kindly gifted
by Ashland (Ashland, Covington, KY, USA). Sodium dihydrogen phosphate, disodium
phosphate, sodium chloride, ethylenediaminetetra acetic acid (EDTA), methylparaben,
and propylparaben were USP grade (where applicable) and obtained from Sigma-Aldrich
(Sigma-Aldrich, St. Louis, MO, USA). Deionized water was Milli-Q grade.
Preparation of the suspensions: Test formulations (INDO1-INDO6) differed in terms of
viscosity and particle size, according to Table 1. Viscosity was varied by using different
grades of HPMC, in order to obtain low (≈1.3 mPa·s, HPMC E) (IND01 and IND04),
medium (≈7 mPa·s, HPMC 4000) (IND02 and IND05), and high (15 mPa·s, HPMC K35M)
(IND03 and IND06) viscosity formulations. In addition, test suspensions had either small
(IND01-IND03) or large (IND04-IND06) particle sizes that were obtained by wet-milling.
Table 2 contains a summary of ingredients and their respective concentrations for each of
the test suspensions (50 mL).
Table 1. Preparation conditions for indomethacin formulations.
Sample Particle Size Milling Parameters * Viscosity Calculated Viscosity (mPa·s)
INDO1 Small Six cycles at 700 rpm with 1 mm pearls Low ≈1.3 (HPMC E5)
INDO2 Small Six cycles at 700 rpm with 1 mm pearls Medium ≈7 (HPMC 4000)
INDO3 Small Six cycles at 700 rpm with 1 mm pearls High ≈15 (HPMC K35M)
INDO4 Large One cycle at 1000 rpm with 5 mm pearls Low ≈1.3 (HPMC E5)
INDO5 Large One cycle at 1000 rpm with 5 mm pearls Medium ≈7 (HPMC 4000)
INDO6 Large One cycle at 1000 rpm with 5 mm pearls High ≈15 (HPMC K35M)
* each test formulation with small (IND01-IND03) or large (IND04-IND06) particle size was prepared separately using the same
milling conditions.
Table 2. Indomethacin test formulations.
Formulation Component Role Concentration
Indomethacin
(pre-milled to a certain particle size) Active pharmaceutical ingredient 0.5 wt.%
HPMC Wetting and viscosity-increasing agent 0.3 wt.%
Sodium dihydrogen phosphate, disodium phosphate Buffering agents 78.16 and 9.84 mM
Sodium chloride Tonicity adjusting agent 35 mM
EDTA Chelating agent 0.05%
Methylparaben Preservative 0.0205%
Propylparaben Preservative 0.026%
Deionized water Aqueous vehicle ad 50 mL
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Wet milling: Wet milling was carried out using a Pulverisette 7 (Fritsch, Idar-Oberstein,
Germany) mill equipped with 45 mL zirconium oxide bowls and 70 g of 1 or 5 mm diameter
pearls. Micronized indomethacin (2 g) was milled in stabilizer solution (10 mL) with 1 mm
diameter pearls at 700 rpm for 6 × 3 min cycles with 15 min cooling breaks to produce
small particles approximately 600 nm in diameter. Larger particles were produced by
milling with 5 mm diameter pearls for one cycle at 1000 rpm. HPMC 4000 (0.5 wt.%) was
used as a stabilizer. The drug and stabilizer solution were both added into the milling
bowl before milling was initiated. The remaining formulation components (as indicated in
Table 2), along with 1.5 g of the milled suspension, were added to pre-dissolved HPMC
solution of predefined grade. The formulations with the same particle size (INDO1-INDO3
and IND04-IND06) were prepared separately using the same milling conditions.
pH and buffer capacity: The pH was measured using a Fieldlab pH meter with a Schott
Blueline 16pH probe. The system was calibrated with pH 4 and 7 buffer solutions. The
buffer capacity of the commercial suspensions was measured (in combination with pH) to
determine the concentration of buffer in the commercial suspensions. Buffer capacity (β) is
related to the change in number of moles of an acid or base (dn) and the associated change
in pH (dpH) for 1 L equivalent of solution: β = dn/dpH.
The pH of 2 mL of the commercial suspensions was measured before and after addition
of 500 µL of sodium hydroxide (0.104 mol/L) to the Indom suspension.
Osmolality: The osmolality of the ocular suspensions was measured using an auto-
osmometer osmostat OM-6020 (Daiichi Kagaku, Kyoto, Japan). The osmometer was
calibrated with Milli-Q water and 300 and 1000 mOsm/kg standard solutions.
Viscosity: The viscosity of the Indom suspension was measured using an AR2000
rheometer (TA instruments, New Castle, DE, USA), which was controlled using Rheology
Advantage software. A cup and rotor setup were used, consisting of the standard cup with
a DIN rotor (TA instruments, New Castle, DE, USA). Viscosity of INDO1-6 was estimated
based on HPMC grade specifications.
X-ray powder diffraction: X-ray powder diffraction (XRPD) for solid-state form confirma-
tion was carried out using a D8 discover XRD system (Bruker Optik, Ettlingen, Germany).
The primary side configuration consisted of a Cu-tube, WL = 1.54 Å; motorized slit (vari-
able); and a 2.5◦ axial soller. The secondary side configuration included a 3◦ anti-scatter slit,
2.5◦ axial soller, 0.02 mm Ni-filter, and a LYNXEYE detector (Bruker, Karlsruhe, Germany)
in 1D mode, fully open (192 slits). For the bulk powders the standard sample holder was
used. The parameters for the bulk powders consisted of an angular range of 3◦ to 41◦, step
size of 0.0161◦, and time/step of 0.36 s to give a total measurement time of 15 min. The
slit was varied between 12 and 22 mm based on the size of a smooth sample surface. The
particles from the suspensions were measured using a zero-background sample holder.
The variable slit was set to 4 mm.
Particle size distribution: Laser light diffraction for particle sizing was carried out with
a Mastersizer 2000 setup including the Hydro 2000s attachment (Malvern Instruments
Ltd., Worchestershire, UK). The background was collected using Milli-Q water. The
solutions were measured diluted in Milli-Q water (~200 mL) to concentrations that gave
the appropriate response levels. The results were calculated based on the default refractive
index (n = 1.52). Five or 10 measurements were collected and averaged. A pump/stirrer
speed of 2975 rpm was used to stir the sample during measurements.
Indomethacin absorption experiments: New Zealand albino rabbits (weight 2.5–3.0 kg)
were used in the experiments. The rabbits were handled in accordance with the statement
of the Animals in Research Committee of ARVO (Association for Research in Vision and
Ophthalmology, Rockville, Maryland, MD, USA). All animal experiments were approved
by the national Animal Experiment Board of Finland (Eläinkoelautakunta, ELLA; license
ESAVI/8893/04.10.07/2014). The animals were kept in conventional housing units involv-
ing set temperatures, humidity and a 12/12 h light/dark cycle. The animals lived under
normal diet, and they were housed freely on floors in the animal rooms. Indomethacin for-
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mulations (INDO1, INDO2, INDO3, INDO4, INDO5, INDO6, Indom) were tested in vivo
in rabbits for kinetics in the tear fluid, cornea, and aqueous humor.
Tear fluid sample collection: The ophthalmic suspensions were administered onto the
upper cornea-scleral limbus of the rabbit eye (25 µL/eye; n = 8–12; indomethacin concentra-
tion 0.5%). The tear fluid samples of 1 µL were withdrawn from each eye with disposable
microcapillaries (Microcaps, Drummond Scientific, Broomall, PA, USA) at time points 1, 3,
5, 10, 20, 30, 60, and 120 min post-instillation, and the samples were immediately cooled on
ice following the storage at −80 ◦C until further analyses.
Aqueous humor and cornea sample collection: The indomethacin suspensions were ad-
ministered onto the upper cornea-scleral limbus of the rabbit eye (25 µL/eye; n = 5 eyes).
The animals were sacrificed at designated times (15, 30, 60, 90, 120 and 240 min) after instil-
lation by injecting a lethal dose of pentobarbital (Mebunat vet 60 mg/mL; Orion Pharma)
into the marginal ear-vein. The eyes were enucleated, aqueous humor was withdrawn
from anterior chamber and corneal tissue was dissected and weighed. Corneal samples
were diluted 1:10 with 0.9% sodium chloride and homogenized using Ultra-Turrax®. The
aqueous humor and corneal samples were frozen in liquid nitrogen and stored at −80 ◦C
prior to the analyses.
Quantification of indomethacin in biological samples: Tear fluid samples were thawed
on ice for 10 min following 1 min of spinning at 13,000 rpm (4 ◦C). The samples were
diluted with 50% acetonitrile containing internal standard (indomethacin-d4) at 20 ng/mL
concentration. Standard curve dilutions (0.5–500 ng/mL; three parallels) were prepared
using indomethacin stock solution (1 mg/mL; 50% acetonitrile) with the internal standard.
Quality controls were prepared in diluted blank tear fluid samples.
The thawed aqueous humor and cornea samples were diluted 1:5 in 0.9% sodium
chloride solution. Diluted samples of 150 µL and internal standard (15 ng/mL) of 10 µL
were pipetted into glass vials for drug extraction. The samples were vortexed, and 1 mL of
methyl tertiary butyl ether (MTBE) was added to each sample. The samples were shaken
vigorously for 10 min, and phases were allowed to separate for 15 min at room temperature.
Organic phase containing the extracted indomethacin was transferred to new glass vials
and evaporated in a vacuum centrifuge. The dried residue was solubilized in 50 µL of 30%
acetonitrile. Standard curves (0.02–500 ng/mL) were prepared in 0.9% sodium chloride,
and MTBE extraction was performed as described above.
Quantitative analyses were performed using LC-MS/MS, involving an Agilent 1290 se-
ries liquid chromatograph and an Agilent 6495 triple-quadrupole mass spectrometer (Ag-
ilent Technologies, Inc., Santa Clara, CA, USA) with electrospray ionization. Separation
was performed with a Poroshell 120 SB-C18 column (2.1 × 50 mm, 2.7 µm, Agilent, Santa
Clara, CA, USA) and Poroshell 120 SB-C18 guard column (2.1 × 5 mm, 2.7 µm, Agilent).
The column was maintained at 50 ◦C. A binary mobile phase with gradient elution was
used (A: 0.1% formic acid in mQ-H2O; B: 100% methanol). The gradient was performed
as follows: 40% of B mobile phase was increased to 100% of B in 5 min, kept constant for
0.5 min, then 100% of B was decreased to 40% of B in 0.1 min and kept constant for 1.4 min.
The total run time was 7 min, the flow rate was 0.3 mL/min, and the injection volume was
2 µL. The MS/MS parameters are presented in Table 3.
Table 3. MS/MS parameters of indomethacin analyses. Positive ion mode was used in elestrospray ionization (ESI).
Compound ESI Precursor Ion Product Ion 1 CE (eV) Product Ion 2 CE (eV) Internal Standard
Indomethacin + 358.01 138.9 17 110.9 49 Indomethacin-d4
Indomethacin-d4 + 364.01 143 16 /
Pharmacokinetic calculations and simulations: Pharmacokinetic parameters of indomethacin
in tear fluid, cornea, and aqueous humor were calculated using non-compartmental data
analyses (Phoenix software, version 6.3, Pharsight Inc., St. Louis, MO, USA). The impact of
dissolution rate and precorneal retention of indomethacin suspensions on ocular absorption
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was simulated with STELLA Professional software (v. 10, ISEE Systems, Lebanon, NH,
USA). Hypothetical dissolution rates in sink conditions (0 to 0.08 min−1) were used in
the simulations at time = 0, and thereafter the in vivo dissolution rate was dependent on
indomethacin solubility and its dissolved concentration in the lacrimal fluid (for the model,
see Figure S6). The dissolution rate was determined with equation: A × K (S-C)/C, where
A is the remaining undissolved indomethacin, K is the first-order dissolution rate constant
in the sink conditions, S is the water solubility of indomethacin, and C is the simulated
concentration of indomethacin in the tear fluid. Loss of free drug from the tear fluid was
based on known clearance factors for small molecules [1,4,21], whereas the retention of the
suspended particles in the tear fluid was varied using first-order rates of elimination in
the range of 0.05 to 0.3 min−1 (corresponding to half-lives of 2.3–14 min). Typical small
molecule values for corneal permeation, distribution volume in anterior chamber, and
elimination from the anterior chamber were used for indomethacin (Table S2).
3. Results
3.1. Physical and Chemical Characterization of the Suspensions
Particle size, viscosity, pH, and osmolality of one test suspension (INDO5) were ad-
justed to be similar to the commercial product Indom® (Table 4). The buffer capacity of
Indom® was approximately 0.020, which corresponds to buffer component concentrations
of 78.2 mM of sodium dihydrogen phosphate and 9.8 mM of disodium phosphate. The
concentrations of EDTA (500 µg/mL), methylparaben (205 µg/mL), and propylparaben
(260 µg/mL) in Indom were measured by ultra-performance liquid chromatography
(UPLC) (see Supplementary Materials).
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(µm) Visual Range (µm)
INDO1 0.19 0.22 0.43 2.48 5.90 0.1–2 ≈1.3 (HPMC E5) 241 5.80
INDO2 0.29 0.45 1.33 7.30 14.00 0.1–3 ≈7 (HPMC 4000) 239 5.90
INDO3 0.18 0.22 0.37 3.28 12.81 0.1–4 ≈15 (HPMC K35M) 239 5.84
INDO4 0.69 1.22 3.23 5.56 7.21 0.4–4 ≈1.3 (HPMC E5) 241 5.82
INDO5 0.74 1.50 3.50 6.03 7.40 0.4–3 ≈7 (HPMC 4000) 242 5.89
INDO6 0.80 1.32 3.12 6.40 9.42 0.4–4 ≈15 (HPMC K35M) 236 5.91
Indom® 0.90 2.75 5.48 9.06 11.40 0.5–5 (bulk), 20–50 (few) ≈7 (measured) 232 5.90
Particle sizing with laser light diffraction (LLD) shows that different milling conditions
resulted in two distinct groups of suspensions with smaller particles (INDO1-INDO3) with
median diameter (d50) of 0.37–1.33 µm and larger particles (INDO4-INDO6) with d50
of 3.12–3.50 µm (Table 4; Figure S3). The commercial suspension (Indom®) had a d50 of
5.48 µm. Scanning electron microscopy (SEM) images of the suspension particles are shown
in Figures S1 and S2. The ranges of particle sizes observed visually in the SEM images
were largely similar to those measured with LLD. However, LLD indicated presence of
some larger particles that were not observed with SEM. This can be attributed to two
factors; firstly, the number of particles inspected with SEM was much smaller than that of
LLD, making sub-sampling more of a problem, and secondly LLD reports distribution by
volume skewing distribution towards larger particle sizes.
The viscosity of the Indom® suspension was 7 mPa·s. The test suspensions with
medium viscosity (INDO2, INDO5) were designed to have similar viscosity to the Indom®
suspension. The low viscosity formulations (INDO1, INDO4) had a calculated viscosity of
1.3 mPa·s, and high viscosity formulations (INDO3, INDO6) had a calculated viscosity of
15 mPa·s (Table 4).
XRPD results confirmed that raw indomethacin powder and Indom® suspension had
polymorphic form γ (Figure S4). During method development, it was also confirmed that
Pharmaceutics 2021, 13, 452 7 of 13
milling did not induce solid state changes, and thus the test suspensions also contained the
γ form.
3.2. Indomethacin Absorption into Rabbit Eyes
Indomethacin concentrations were monitored in the tear fluid after topical instillation
of the ophthalmic suspensions to the rabbit eyes. It is evident that the particle size and
viscosity have an impact on the time course of indomethacin concentrations in the tear
fluid (Figure 2, left). Increased viscosity in the suspension prolongs the drug retention in
the tear fluid, whereas the smaller particle size decreases indomethacin retention in the
tear fluid (Figure 2, middle, right).
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Figure 2. Left. Mean concentration of indomethacin in the rabbit tear fluid after instillation of the suspensions (Indom®,
INDO1-INDO6). Middle. Indomethacin concentrations (mean ± SEM) in the tear fluid after instillation of the small
particles as low (INDO1), medium (INDO2), and high viscosity (I 3) suspensions. Right. Indo ethacin concentrations
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The data were further analyzed to calculate the AUC values in the tear fluid, based on
the mean indomethacin concentrations over time (Table 5). AUC was increased 3.5–4.0-fold
with increasing suspension viscosity at similar particle size. Similar fold increase in
AUC values at increasing viscosity was seen for small particles and large particles. The
concentrations at 1 min (C1mi ) increased 2.4–4.0 ti es with increasing eyedrop viscosity,
but at similar particle size, in the lacrimal fluid. Indomethacin concentrations in the tear
fluid (AUC, C1min) were smaller after instillation of small particles (INDO1-3) than after
application of larger particles (INDO4-6) at similar viscosities.
Table 5. Pharmacokinetic analysis of the indomethacin concentrations in tear fluid. AUC is the area
under the curve until infinity.
Formulation AUC(min × µg/mL) CV%
C1min
(µg/mL) CV%
Indom® 6312 25 216 33
INDO1 1299 15 63 19
INDO2 4379 17 238 20
INDO3 5197 17 299 20
INDO4 6718 20 400 24
INDO5 10,849 19 445 24
INDO6 23,517 11 1480 13
Indomethacin concentrations in rabbit aqueous humor are presented in Figure 3.
Particle size and viscosity have influence on the indomethacin concentrations. Increased
suspension viscosity (INDO3 > INDO2 > INDO1; INDO6 > INDO5 > INDO4) at similar
particle size category increases drug permeation to the aqueous humor for both small and
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large particles (Figure 3). Indomethacin absorption to the aqueous humor (AUC) after
instillation of small particles is higher than that after larger particles with similar viscosity
(Table 6). Increasing viscosity improved ocular bioavailability by 3–4 times for both small
and large particles (Table 6). Topical application of IND05 and Indom® resulted in similar
drug delivery to the aqueous humor (Figure 3, Table 6). Similar trends as in aqueous humor
were also seen in the corneal drug levels (Figure S5).
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3.3. Pharmacokinetic Simulations
Increasing particle retention in the tear fluid (elimination rates: 0.05–0.3 min−1 in tear
fluid) increased the simulated AUC in the aqueous humor about 4-fold, whereas increasing
the rate of dissolution at sink conditions (from 0.01 to 0.08 min−1) increased AUC in
aqueous humor about 2-fold (Figure 5). The simulated and observed AUC values from
Table 6 are in the same range (Figure 5). In the case of simulations with induced lacrimation
factor, the AUC levels in aqueous humor after instillation of small particle susp nsion were
in the range of the simulat d AUC valu s at high issolution rates (≈0.08 min−1), whereas
the AUC values of large particle suspe sions were a better match with the simulated value
for slow dissolution. Without induced lacr mation, the simulated AUC values increased to
about 1.5-fold higher levels (Figure 5).
4. Discussion
The results of this study show that the viscosity of ophthalmic suspensions has a
clear impact on ocular indomethacin absorption. Increasing viscosity from 1.3 to 15 mPa
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resulted in about 4-fold increase in ocular absorption (i.e., AUC in aqueous humor). Thus,
viscosity should be an important consideration when ophthalmic suspensions are formu-
lated. Previous studies showed that higher viscosity increases ocular drug absorption
from eye drop solutions [22,23] and budesonide suspension [9]. On the other hand, it is
known that increased viscosity increases the thickness of unstirred water layer around drug
particles [24], but this factor should decrease dissolution rate and reduce drug absorption.
Thus, thickening of the unstirred water layer around suspension particles is not important
in vivo, and the impact of viscosity on drug retention on the ocular surface is the dominant
factor. It should be noted that rheological flow properties have an impact on ocular drug
absorption. This is relevant if polymers with non-Newtonian rheology and pseudoplastic
spreading characteristics on the ocular surface are used (e.g., caroboxymethylcellulose,
hydoxypropylcellulose) [25]. Apparently, higher eyedrop viscosity is able to retain the
suspension particles and solution in the tear fluid, as shown in the tear fluid data of in-
domethacin concentrations (Table 5). It is important to note that capillary samples of tear
fluid include both dissolved and undissolved indomethacin.
A smaller particle size in a suspension results in increased surface to volume ratio
and faster drug dissolution. In the case of indomethacin, faster dissolution from smaller
particles leads to higher ocular drug absorption; the suspension with small particle size
(0.4–1.3 µm) showed approximately two times higher drug delivery to the aqueous humor
as compared to large particle (3.1–3.5 µm) suspensions. Interestingly, the suspensions with
small indomethacin particles were actually removed faster from the tear fluid than the larger
particles, as the AUC values in the tear fluid decreased with smaller particle size (Figure 2).
Despite their faster lacrimal elimination and lower AUC in tear fluid, the small particle
suspensions resulted in improved drug absorption into the eye (Figure 4). An identical
relationship between AUC values in tear fluid and in aqueous humor should be seen if the
fraction of the dissolved drug in the tear fluid is identical in both cases. Compared to larger
particles, a higher proportion of indomethacin dissolves in the tear fluid after application
of small particles, thereby leading to improved ocular drug absorption. Thus, retention of
the suspension in the tear fluid does not correlate linearly with drug absorption (Figure 5).
Pharmacokinetic simulations were performed to probe the impact of particle dissolu-
tion in the ocular indomethacin absorption. Since exact parameter values for indomethacin
were not available, we used parameter values that are expected for indomethacin (non-
productive clearance from lacrimal fluid with and without induced lacrimation, clearance
from lacrimal fluid to the cornea, clearance from aqueous humor) (Figure S6, Table S2).
Simulations of indomethacin AUC in the aqueous humor at various retention times and
dissolution rates of suspended particles resulted in realistic results that matched the ex-
perimental observations, especially when induced lacrimation was included in the model
(Figure 4). The simulations reveal some interesting aspects. Firstly, increased drug disso-
lution rate yields higher ocular bioavailability, but the increase is not linear, suggesting
that the sink conditions may not prevail in the lacrimal fluid. Secondly, increased retention
of the particles on the ocular surface results in higher AUC in the aqueous humor, but
this increase is also non-linear (about 4-fold increase in AUC, whereas the elimination
rate constants vary over a 6-fold range). Previous simulations also suggest non-linear
behavior of ophthalmic dexamethasone suspensions [26]. We do not know the absolute
bioavailability of indomethacin in the aqueous humor because intracameral clearance
of indomethacin is not known. However, it is likely that intracameral clearance of in-
domethacin falls within recently reported range of values (6.4 to 32 µL/min) for intra-
camerally injected small molecules [27]. With these values we can estimate that ocular
bioavailability of indomethacin suspensions with smaller and larger particles is 0.4–1.3%
and 0.2–0.7%, respectively.
Our simulations suggest that the concentrations of dissolved indomethacin in the
lacrimal fluid at the dissolution rates of 0.1–0.8 min−1 are in the range of 3 to 20 and 10 to
23 µg/mL at particle removal rates of 0.05 and 0.3 min−1, respectively. Since water solubility
of indomethacin at neutral pH is 43 µg/mL, we conclude that dissolution of suspended
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particles is affected by the dissolved drug in the tear fluid and the sink conditions may
not prevail in vivo. Earlier publications suggest that only a fraction of fluorometholone
particles dissolve after topical administration in the rabbit eyes [8,10,28]. We can reach this
conclusion because the AUC in aqueous humor increased only ≈2–4-fold with suspensions
as compared to the fluorometholone solution, even though the drug dose in the suspensions
(25 µg) was 67 times higher than in the solution (0.375 µg). Therefore, in vitro dissolution
tests overestimate the rate of suspension particle dissolution, and more realistic dissolution
methods mimicking drug clearance from the tear fluid might provide more accurate
estimation of drug dissolution on the ocular surface.
Bioequivalence of ocular suspensions is not self-evident, even if the suspensions have
similar compositions. Particle size distribution may vary due to the suspension processing,
and this causes changes in drug dissolution and ocular drug absorption. Here we show that
the particle size indeed has influence on drug absorption from the suspensions with equal
viscosity (Figure 3). Likewise, differences in viscosity caused changes in indomethacin
absorption from suspensions with similar particle sizes (Figure 3). The acceptable range
for dissolution rate and viscosity depends on the sensitivity of ocular drug absorption
to these parameters. Typically, the AUC values of generic products should be within
80% to 125% of the originator values [29,30]. The changes in particle size and viscosity
of the suspensions in this study resulted in greater changes in the AUC values, but the
simulations in Figure 4 give some hints about the sensitivity of AUC to the dissolution
rate in sink conditions. For example, if we consider the medium viscosity formulation and
dissolution rate of 0.04 min−1, it seems that dissolution rates of 0.03–0.06 min−1 yield mean
AUC values within the bioequivalence limits. This theoretical consideration, however, does
not take into account important inter-subject variability factors [20]. Clinical variability
is also affected by the sedimentation rate of the suspensions. The patients should shake
the suspension bottle before eye drop instillation, but the time between shaking, and
instillation may vary as well as the sedimentation rate. In this study, the suspensions were
instilled immediately after shaking to minimize the impact of sedimentation.
5. Conclusions
Biopharmaceutical properties of topical ocular suspensions are still poorly understood.
Herein, we demonstrate that particle size and viscosity of indomethacin suspensions
affect ocular bioavailability over about an 8-fold range. Increased viscosity increased
ocular indomethacin absorption 2.5–3.5-fold for suspensions with similar particle sizes,
while smaller particle size increased absorption from equiviscous suspensions 1.6–2.3-fold.
Remarkably, total indomethacin concentrations in the tear fluid were disconnected from the
ocular bioavailability, as suspensions with larger particles had higher AUC values in the
tear fluid than the small particle suspension. These data and simulations suggest that only
a fraction of the suspended particles dissolve in tear fluid, and dissolution has a significant
impact on ocular drug bioavailability. The published data and pharmacokinetic insights
will be useful in the development of original and generic ophthalmic suspensions.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/pharmaceutics13040452/s1, Figure S1: SEM images of the INDO1-INDO3 test suspensions at
different magnifications, Figure S2: SEM images of the INDO4-INDO6 suspensions at different mag-
nifications, Figure S3: Particle size distributions of indomethacin suspensions, Figure S4: Calculated
diffractograms for α and γ forms of indomethacin compared with the measured diffractograms for
solid indomethacin and Indom® solid from suspension, Figure S5: Indomethacin concentrations in
the rabbit cornea after topical administration of the suspensions, Figure S6: The simulation model
structure, Table S1: The gradient parameters of the mobile phase used for UPLC of the commercial
suspensions, Table S2: Pharmacokinetic simulation parameters.
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